Two-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age

Conclusion In this second interim analysis, short children born SGA were safely and effectively treated with rhGH (Omnitrope), and 2 years’ treatment had no major adverse impact on carbohydrate metabolism or body mass. Funding Sandoz.

http://link.springer.com/10.1007/s12325-016-0301-1

Source: Advances in Therapy - February 17, 2016 Category: Drugs & Pharmacology Source Type: research